NCT07178457View on ClinicalTrials.gov

Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2032

Study Completion Date

November 1, 2032

Conditions
Cutaneous T Cell Lymphoma (CTCL)Brentuximab Vedotin
Interventions
DRUG

Brentuximab Vedotin (Bv)

1.8 mg/kg in 100 mlof NaCl 0.9%, Q3W with a maximum of 16 cycles

DRUG

Placebo

NaCl 0.9% 100 ml IV Q3W with a maximum of 16 cycles

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER